Hemodialysis of chronic kidney failure patients requiring ablative radioiodine therapy

Kidney Int. 2008 Jun;73(11):1316-9. doi: 10.1038/ki.2008.95. Epub 2008 Mar 19.


Ablative radioiodine therapy is the standard treatment for thyroid carcinoma, but as (131)I is predominantly cleared by renal excretion, its clearance will be reduced in patients with chronic kidney disease, particularly in anuric patients on dialysis. The high dose of radioactivity used in the procedure results in an increased risk of radioactive exposure to the patient, the dialysis staff, and the machinery. Here, we describe how to successfully hemodialyze patients with chronic kidney failure requiring ablative (131)I therapy for thyroid cancer while minimizing risks to the patient and dialysis staff. With appropriate training, hemodialysis treatments can be safely delivered to patients receiving radiotherapy.

MeSH terms

  • Carcinoma / complications
  • Carcinoma / radiotherapy*
  • Humans
  • Iodine Radioisotopes / adverse effects*
  • Iodine Radioisotopes / pharmacokinetics
  • Iodine Radioisotopes / therapeutic use
  • Kidney Failure, Chronic / complications
  • Kidney Failure, Chronic / therapy*
  • Medical Staff, Hospital
  • Radiation Dosage
  • Radiation Protection
  • Renal Dialysis / methods*
  • Thyroid Neoplasms / complications
  • Thyroid Neoplasms / radiotherapy*


  • Iodine Radioisotopes